Reaction
Intraductal Proliferative Breast Lesion reporting signals
As of the last recalculation, Intraductal Proliferative Breast Lesion appears in 1,243 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is ANASTROZOLE TABLETS (PRR 21.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Anastrozole Tablets | 27 | 21.5 | 21.5 |
| Anastrozole | 33 | 15.4 | 15.4 |
| Pertuzumab | 20 | 12.5 | 12.5 |
| Baricitinib | 6 | 10.5 | 10.5 |
| Ado-Trastuzumab Emtansine | 5 | 10.0 | 10.0 |
| Fingolimod Hcl | 45 | 9.0 | 9.0 |
| Natalizumab | 90 | 8.9 | 8.9 |
| Ribociclib | 16 | 8.6 | 8.6 |
| Daratumumab | 19 | 8.1 | 8.1 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 4 | 7.8 | 7.8 |
| Ocrelizumab | 28 | 7.7 | 7.7 |
| Bendamustine Hcl | 7 | 7.6 | 7.6 |
| Ravulizumab | 5 | 6.2 | 6.2 |
| Interferon Beta-1A | 66 | 6.0 | 6.0 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 8 | 5.7 | 5.7 |
| Ranitidine Hydrochloride | 18 | 5.6 | 5.6 |
| Dalfampridine | 18 | 4.2 | 4.2 |
| Diroximel Fumarate | 3 | 4.2 | 4.2 |
| Dimethyl Fumarate | 30 | 4.2 | 4.2 |
| Levonorgestrel | 39 | 3.3 | 3.3 |
| Pomalidomide | 16 | 2.6 | 2.6 |